UB Paderborn / Katalog / Suche / in CDI

Bone health and osteoporosis in postmenopausal women

Best practice & research. Clinical obstetrics & gynaecology, 2009-02, Vol.23 (1), p.73-85

Johannes de Villiers, Tobias, MBChB, MMed (O&G), MRCOG, FCOG (SA)

2009

Link zum Volltext

Verfügbarkeit prüfen

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis

Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1113-1119

2021

Link zum Volltext

Verfügbarkeit prüfen

Exercise and risk reduction for osteoporosis IMS symposium: 20th May

Maturitas, 2015-05, Vol.81 (1), p.123-123

De Villiers, Tobias J

2015

Link zum Volltext

Verfügbarkeit prüfen

Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial

Bone Reports, 2020-10, Vol.13, p.100326, Article 100326

2020

Link zum Volltext

Verfügbarkeit prüfen

The management of vasomotor symptoms of menopause (VMS) with menopausal hormone therapy (MHT)

Current opinion in endocrine and metabolic research, 2022-12, Vol.27, p.100420, Article 100420

De Villiers, Tobias

2022

Link zum Volltext

Verfügbarkeit prüfen

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Journal of bone and mineral research, 2021-11, Vol.36 (11), p.2139-2152

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5‐Year Data From the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension

Journal of bone and mineral research, 2020-07, Vol.35 (7), p.1289-1299

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis

Obstetrics and gynecology (New York. 1953), 2003-04, Vol.101 (4), p.711-721

2003

Link zum Volltext

Verfügbarkeit prüfen

Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial

The journal of clinical endocrinology and metabolism, 2013-12, Vol.98 (12), p.4727-4735

2013

Link zum Volltext

Verfügbarkeit prüfen

NOFSA statement on the appropriate management of osteoporosis in the elderly – myth and reality

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2016-11, Vol.21 (3), p.1-2

2016

Link zum Volltext

Verfügbarkeit prüfen

NAMS 3rd Utian Translational Science Symposium, October 2016, Orlando, Florida A conversation about hormone therapy: is there an appropriate dose, route, and duration of use?

Menopause (New York, N.Y.), 2017-11, Vol.24 (11), p.1221

The North American Menopause Society (NAMS)

2017

Link zum Volltext

Verfügbarkeit prüfen

Selective estrogen receptor modulators in the treatment of osteoporosis: a review of the clinical evidence

Clinical investigation, 2011-05, Vol.1 (5), p.719-724

de Villiers, Tobias Johannes

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Alendronate Plus Vitamin D3 Versus Standard Care in Osteoporotic Postmenopausal Women with Vitamin D Insufficiency

Calcified tissue international, 2011-06, Vol.88 (6), p.485-494

2011

Link zum Volltext

Verfügbarkeit prüfen

Aging, menopause, cardiovascular disease and HRT

Climacteric : the journal of the International Menopause Society, 2009, Vol.12 (5), p.368-377

2009

Link zum Volltext

Verfügbarkeit prüfen

Estrogens, Selective Estrogen Receptor Modulators, and Tissue‐Selective Estrogen Complex

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2018, p.541-544

2018

Link zum Volltext

Verfügbarkeit prüfen

Bone health and osteoporosis in postmenopausal women: Menopause and Menopause Transition

Best practice & research. Clinical obstetrics & gynaecology, 2009, Vol.23 (1), p.73-85

DE VILLIERS, Tobias Johannes

2009

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Equivalence of Alendronate 35 Milligrams Once Weekly and 5 Milligrams Daily in the Prevention of Postmenopausal Osteoporosis

Obstetrics and gynecology (New York. 1953), 2003-04, Vol.101 (4), p.711-721

2003

Link zum Volltext

Verfügbarkeit prüfen

Fingerprints and palmar prints of Kalahari Bushmen

South African journal of science, 1961-12, Vol.57 (12), p.333-345

Tobias, P.V., Soussi, J. & De Villiers, H.L.A.

1961

Link zum Volltext

Verfügbarkeit prüfen

Associations between ventilator settings during extracorporeal membrane oxygenation for refractory hypoxemia and outcome in patients with acute respiratory distress syndrome: a pooled individual patient data analysis: Mechanical ventilation during ECMO

Intensive care medicine, 2016-11, Vol.42 (11), p.1672-1684

2016

Link zum Volltext

Verfügbarkeit prüfen

Certolizumab Pegol for the Treatment of Crohn's Disease

The New England journal of medicine, 2007-07, Vol.357 (3), p.228-238

2007

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Bone health and osteoporosis in postmenopausal women

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis

Exercise and risk reduction for osteoporosis IMS symposium: 20th May

Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial

The management of vasomotor symptoms of menopause (VMS) with menopausal hormone therapy (MHT)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5‐Year Data From the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis

Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial

NOFSA statement on the appropriate management of osteoporosis in the elderly – myth and reality

NAMS 3rd Utian Translational Science Symposium, October 2016, Orlando, Florida A conversation about hormone therapy: is there an appropriate dose, route, and duration of use?

Selective estrogen receptor modulators in the treatment of osteoporosis: a review of the clinical evidence

Randomized Trial of Alendronate Plus Vitamin D3 Versus Standard Care in Osteoporotic Postmenopausal Women with Vitamin D Insufficiency

Aging, menopause, cardiovascular disease and HRT

Estrogens, Selective Estrogen Receptor Modulators, and Tissue‐Selective Estrogen Complex

Bone health and osteoporosis in postmenopausal women: Menopause and Menopause Transition

Therapeutic Equivalence of Alendronate 35 Milligrams Once Weekly and 5 Milligrams Daily in the Prevention of Postmenopausal Osteoporosis

Fingerprints and palmar prints of Kalahari Bushmen

Associations between ventilator settings during extracorporeal membrane oxygenation for refractory hypoxemia and outcome in patients with acute respiratory distress syndrome: a pooled individual patient data analysis: Mechanical ventilation during ECMO

Certolizumab Pegol for the Treatment of Crohn's Disease

Suchergebnisse filtern